Sinocelltech Ltd.

Chunyun Sun

Jun Zhao

Jing Li

Rui Wang

Xiao Lin Zhang

Xiao Xun Zhang

Xiao Zhang

Liangzhi Xie

Tianjiao Liu

Juan Ma

Desheng Kong

The present disclosure provides a recombinant humanized monoclonal antibody against programmed cell death receptor-1 (PD-1) or an antigen-binding fragment thereof, which can be used in tumor or cancer immunotherapy. The disclosure also provides nucleic acid sequences encoding said antibody or antigen-binding fragment thereof, vectors containing said nucleic acid sequences, pharmaceutical compositions and kits.

Humanized anti-PD-1 antibody and the use thereof

The present invention belongs to the field of tumor immunotherapy, and relates to a humanized monoclonal antibody that binds to VEGF. The present invention discloses nucleic acid sequences (including heavy/light chain variable regions) encoding said antibodies, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The antibody disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2. Said antibodies also neutralize the proliferative effect of VEGF165 protein and multiple VEGF subtypes on HUVEC cells and can be used in clinical treatment of tumors, including but not limited to: colorectal cancer.

Humanized anti-VEGF monoclonal antibody

Growing community of inventors

Beijing, China

Chunyun Sun